| Primary |
| Hiv Infection |
61.3% |
| Antiretroviral Therapy |
8.8% |
| Acquired Immunodeficiency Syndrome |
6.9% |
| Prophylaxis Against Hiv Infection |
5.1% |
| Antiviral Treatment |
4.6% |
| Antiviral Prophylaxis |
2.3% |
| Drug Use For Unknown Indication |
2.3% |
| Viral Infection |
2.3% |
| Bacteriuria |
0.9% |
| Nausea |
0.9% |
| Pregnancy |
0.9% |
| Urinary Tract Infection |
0.9% |
| Fatigue |
0.5% |
| Hypertension |
0.5% |
| Hypotension |
0.5% |
| Product Used For Unknown Indication |
0.5% |
| Supplementation Therapy |
0.5% |
| Tuberculosis |
0.5% |
|
| Stillbirth |
16.4% |
| Drug Exposure During Pregnancy |
11.5% |
| Maternal Exposure During Pregnancy |
9.8% |
| Ventricular Septal Defect |
8.2% |
| Congenital Anomaly |
4.9% |
| Premature Baby |
4.9% |
| Vomiting |
4.9% |
| Abortion Spontaneous |
3.3% |
| Cryptorchism |
3.3% |
| Exposure During Pregnancy |
3.3% |
| Foetal Exposure During Pregnancy |
3.3% |
| Gastroschisis |
3.3% |
| Intra-uterine Death |
3.3% |
| Lactic Acidosis |
3.3% |
| Pyelocaliectasis |
3.3% |
| Respiratory Disorder |
3.3% |
| Thrombosis |
3.3% |
| Weight Decreased |
3.3% |
| Anaemia |
1.6% |
| Bradycardia |
1.6% |
|
| Secondary |
| Drug Exposure During Pregnancy |
30.1% |
| Hiv Infection |
29.6% |
| Drug Use For Unknown Indication |
14.3% |
| Antiretroviral Therapy |
5.7% |
| Product Used For Unknown Indication |
3.3% |
| Acquired Immunodeficiency Syndrome |
3.0% |
| Antiviral Treatment |
2.4% |
| Hiv Test Positive |
1.7% |
| Systemic Antiviral Treatment |
1.6% |
| Prophylaxis Against Hiv Infection |
1.6% |
| Maternal Exposure Timing Unspecified |
1.0% |
| Antifungal Prophylaxis |
0.9% |
| Prophylaxis |
0.8% |
| Mycobacterium Avium Complex Infection |
0.7% |
| Tuberculosis |
0.7% |
| Disseminated Tuberculosis |
0.6% |
| General Anaesthesia |
0.6% |
| Diarrhoea |
0.5% |
| Trigeminal Neuralgia |
0.5% |
| Neuropathy Peripheral |
0.5% |
|
| Drug Exposure During Pregnancy |
14.8% |
| Premature Baby |
11.6% |
| Stillbirth |
9.5% |
| Pregnancy |
8.0% |
| Abortion Spontaneous |
7.4% |
| Abortion Induced |
6.5% |
| Ventricular Septal Defect |
6.5% |
| Polydactyly |
5.0% |
| Small For Dates Baby |
4.5% |
| Trisomy 21 |
3.9% |
| Talipes |
3.0% |
| Renal Failure |
2.4% |
| Urine Amphetamine Positive |
2.4% |
| Vanishing Bile Duct Syndrome |
2.4% |
| Cryptorchism |
2.1% |
| Hydrocephalus |
2.1% |
| Respiratory Distress |
2.1% |
| Vomiting |
2.1% |
| White Blood Cell Count Decreased |
2.1% |
| Maternal Drugs Affecting Foetus |
1.8% |
|
| Concomitant |
| Hiv Infection |
44.3% |
| Drug Use For Unknown Indication |
17.9% |
| Prophylaxis |
5.5% |
| Prophylaxis Against Hiv Infection |
5.0% |
| Product Used For Unknown Indication |
4.1% |
| Drug Hypersensitivity |
3.2% |
| Human Immunodeficiency Virus Transmission |
3.0% |
| Drug Exposure During Pregnancy |
2.6% |
| Maternal Exposure During Pregnancy |
2.1% |
| Antifungal Prophylaxis |
1.7% |
| Maternal Exposure Timing Unspecified |
1.4% |
| Routine Health Maintenance |
1.4% |
| Cough |
1.2% |
| Hiv Test Positive |
1.2% |
| Headache |
1.0% |
| Hypertension |
1.0% |
| Antiretroviral Therapy |
0.9% |
| Depression |
0.9% |
| Diarrhoea |
0.9% |
| Arthralgia |
0.8% |
|
| Abortion Spontaneous |
12.5% |
| Vomiting |
11.4% |
| Intra-uterine Death |
10.8% |
| Stillbirth |
7.4% |
| Pre-eclampsia |
5.7% |
| Pancytopenia |
5.1% |
| Haemolytic Anaemia |
4.5% |
| Abortion Incomplete |
4.0% |
| Transaminases Increased |
4.0% |
| Trisomy 21 |
4.0% |
| Anaemia |
3.4% |
| Premature Baby |
3.4% |
| Pyrexia |
3.4% |
| Vaginal Haemorrhage |
3.4% |
| Death |
2.8% |
| Foetal Exposure During Pregnancy |
2.8% |
| Nausea |
2.8% |
| Pregnancy |
2.8% |
| Premature Rupture Of Membranes |
2.8% |
| Pulmonary Tuberculosis |
2.8% |
|
| Interacting |
| Hiv Infection |
61.5% |
| Hepatitis C Virus |
23.1% |
| Drug Use For Unknown Indication |
15.4% |
|
| Lipodystrophy Acquired |
50.0% |
| Polyneuropathy |
50.0% |
|
